^
    Back
    Association details:
    Biomarker:EGFR S492R
    Cancer:Colorectal Cancer
    Drug:Vectibix (panitumumab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Nat Med
    Title:

    Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

    Excerpt:
    A subject with cetuximab resistance harboring the S492R mutation responded to treatment with panitumumab.
    DOI:
    10.1038/nm.2609
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Int J Cancer
    Title:

    Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab

    Published date:
    06/10/2019
    Excerpt:
    Here, through systematic functional screening of 21 recurrent EGFR mutations selected from public data sets, we show that 11 colon cancer-derived EGFR mutants (G63R, E114K, R165Q, R222C, S492R, P596L, K708R, E709K, G719S, G724S and L858R) are oncogenic…these EGFR mutants are inhibited by cetuximab or panitumumab in vivo and in vitro. Taken together, we propose that a subset of EGFR mutations can serve as genomic predictors for response to anti-EGFR antibodies and that metastatic CRC patients with such mutations may benefit from these drugs as part of the first-line therapy.
    DOI:
    10.1002/ijc.32499